Early intervention with epoetin alfa during platinum-based chemotherapy: An analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level

Oncologist

Volumn 11, Issue 2, 2006, Pages 206-216

  Savonije, Jorine H ^a   Van Groeningen, Cees J ^a   Wormhoudt, Lars W ^b   Giaccone, Guiseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Janssen Cilag BV Netherlands   (Netherlands)

Author keywords

Anemia; Cancer; Epoetin alfa; Hemoglobin; Quality of life

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; HEMOGLOBIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; EPOETIN ALFA; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLATINUM COMPOUNDS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 32944473572     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-2-206     Document Type: Article

References (29)

1. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
2. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-373.
3. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
4. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179.
5. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(suppl 2):S2-S8.
6. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
7. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
8. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
9. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
10. Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-1353.
11. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
12. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
13. Silberstein PT, Witzig TE, Sloan JA et al. Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group. Proc Am Soc Clin Oncol 2002;21:356a.
14. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
15. Rodgers GM, Cella D, Chanan-Khan A et al. Cancer and treatment-related anemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v.2.2005. Available at http//:www.neen.org. Acessed July 14, 2005.
16. Grote TH, Castillo R, Fishkin E et al. Effects of early intervention with epoetin alfa in patients with small cell lung cancer. Lung Cancer 2003;41:S3-314.
17. Milroy R, Scagliotti G, van den Berg PM et al. Early intervention with epoetin alfa maintains hemoglobin in advanced non-small-cell lung cancer patients. Lung Cancer 2003;41:S3-314.
18. Straus DJ, Testa M, Riggs SA et al. Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). Blood 2003;102:497a.
19. Savonije JH, van Groeningen CJ, van Bochove A et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 2005;41:1560-1569.
20. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
21. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2):13-19.
22. Cella D, Webster KA. Quality of life and treatment value in the management of hematologic malignancies. Semin Oncol 1999;26(suppl 14)34-42.
23. Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Cancer Netw 2004;2:509-517.
24. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
25. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605.
26. Hudis CA, Vogel CL, Gralow JR et al. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer 2005;6:132-142.
27. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
28. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972.
29. Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-498.